

TABLE OF CONTENT

Sr. No	Content	Page No.
	LIST OF FIGURES	i - viii
	LIST OF TABLES	ix - xii
	LIST OF ABBREVIATIONS AND SYMBOLS	xiii - xvi
	PREFACE	xvii - xviii
CHAPTER 1		1 - 4
<hr/>		
INTRODUCTION AND OBJECTIVES		
<hr/>		
1.1.	Background	1
1.2.	Motivation and significance of research work	3
1.3.	Objectives	4
CHAPTER 2		5 - 24
<hr/>		
LITERATURE REVIEW		
<hr/>		
2.1.	Snake Venom	6
2.2.	Composition of snake venom	6
2.3.	Anti-venom	7
2.4.	Side effects of Anti-venom	8
2.5.	Anti venom issues	8
2.6.	Herbal as a choice	9
2.7.	<i>Azadirachta. Indica</i>	15
2.8	Cancer	15
2.8.1.	Liver cancer	17
2.8.2.	Prostate cancer	17
2.8.3.	Ovarian cancer	18
2.8.4.	Herbal choice as an anticancer agent	18
2.8.5.	Gedunin as an anticancer agent	20

2.9.	Gedunin (C ₂₈ H ₃₄ O ₇) as anti diabetic agent	24
------	--	----

CHAPTER - 3 27 - 36

**EXTRACTION, PURIFICATION, AND
CHARACTERIZATION FROM OF GEDUNIN**

AZADIRACHTA INDICA

3.1.	Introduction	27
3.2.	Experimental	29
3.2.1	Collection of plant material	29
3.2.2	Extraction and characterization	29
3.3.	Results and Discussion	31
3.4.	Conclusion	35

CHAPTER 4 37 - 54

**COMPUTATIONAL ANALYSIS OF A GEDUNIN AS A
POTENTIAL INHIBITOR OF SNAKE VENOM ENZYMES**

4.1.	Introduction	37
4.2.	Experimental	39
4.2.1.	Computational methods	39
4.2.1.1.	Molecular Docking	39
4.2.1.1.1.	Ligand Preparation	39
4.2.1.1.2.	Receptor Preparation	39
4.2.2	Simulation	40
4.2.3.	ADMET	40
4.2.4.	Toxicity	40
4.3.	Results and Discussion	40
4.3.1.	Molecular Docking	40
4.3.2.	Simulation	43

4.3.3.	Pharmacokinetics	45
4.3.4.	Drug–Likeliness and Medicinal chemistry Using SwissADME	47
4.3.5.	Metabolism	48
4.3.6.	Toxicity	50
4.4	Conclusion	54

CHAPTER 5

55 - 78

**COMPUTATIONAL ANALYSIS OF MODIFIED
GEDUNIN COMPOUND (C₂₆H₃₁N₂O₆F) AS A POTENTIAL
INHIBITOR OF SNAKE VENOM ENZYMES**

5.1.	Introduction	55
5.2.	Experimental	56
5.2.1.	The ICM Method	56
5.2.1.1.	Ligand Preparation	57
5.2.1.2.	Receptor Preparation	58
5.2.1.3.	Molecular Docking	58
5.2.2	Simulation	61
5.2.3.	Pharmacokinetics Analysis	61
5.3.	Results and Discussion	62
5.3.1.	Molecular Docking	62
5.3.2.	Simulation	64
5.3.3.	ADME	66
5.3.4.	Toxicity	73
5.4.	Conclusion	78

CHAPTER: 6

79 - 110

QSAR AND RETROSYNTHESIS OF GEDUNIN

AND MODIFIED GEDUNIN

6.1.	Introduction	79
6.2	Experimental	81
6.2.1	QSAR	81
6.2.1.1	Data Sets	81
6.2.1.2	Molecular Descriptors	81
6.2.1.3	Machine Learning Methods	82
6.2.1.4	Validation and Cross-Validation	83
6.2.2	Retrosynthesis	83
6.3	Statistical analysis	84
6.4	Results and Discussion	84
6.4.1	Good Model Criteria	85
6.4.1.1	Regressing on the predicted Test set	85
6.4.1.2	q^2 of the training set > 0.5, with cross-validation	85
6.4.1.3	RMSE of Test set < 10%.	85
6.4.2	Log P Model	86
6.4.3	Log IC50 Model	88
6.4.4	Graph Analysis of Log IC50 model using Stardrop	89
6.5	Conclusion	109

CHAPTER 7

111 - 123

MOLECULAR PROPERTY PREDICTION OF
GEDUNIN (C₂₆H₃₁N₂O₆F) USING
MACHINE LEARNING

7.1	Introduction	111
7.2	Experimental	114
7.2.1	Datasets	114
7.2.2	Feature Extraction and clustering	115
7.2.3	Prediction	115
7.3	Results and Discussion	115

7.3.1	CNN	117
7.3.2	Transfer Learning	120
7.3.3	K-means Clustering	121
7.3.4	Long short-term memory (LSTM)	121
7.4	Conclusion	122

CHAPTER 8

124 - 145

**ANTI DIABETIC POTENTIAL OF GEDUNIN
USING ENZYME KINETICS AND IN SILICO STUDY**

8.21	Introduction	124
8.2	Experimental	128
8.2.1	Molecular Docking	128
8.2.2	Simulation	129
8.2.3	Alpha-amylase inhibition assay	129
8.2.3.1	Mode of inhibition	130
8.2.4	Alpha Glucosidase Inhibition assay	130
8.2.4.1	Mode of Inhibition	131
8.3	Results and Discussion	132
8.3.1	Molecular Docking	132
8.3.2	Simulation	137
8.3.3	Alpha Amylase and alpha glucosidase inhibition	142
8.4	Conclusion	145

CHAPTER 9

146 - 202

**ANTICANCER ACTIVITY OF GEDUNIN FROM
AZADIRACHTA INDICA AGAINST NON CANCEROUS**

**CELL LINE, LIVER CANCER CELL LINE HEPG2,
PA1 OVARIAN AND PC3PROSTATE CANCER CELLS**

9.1	Introduction	146
9.2	Experimental	150
9.2.1	Molecular Docking	150
9.2.2	Simulation	152
9.2.3	MTT Assay	153
9.2.4	ROS Activity Detection	154
9.2.5	Apoptosis Assay	155
9.2.6	Scratch assay / Cell migration assay	157
9.2.7	Colony formation assay / cell proliferation assay.	158
9.3	Result and Discussion	159
9.3.1	Molecular Docking	159
9.3.2	Simulation	161
9.3.3	MTT analysis of gedunin	165
9.3.4	Evaluation of ROS activity assay using HepG2 cell line	177
9.3.5	Evaluation of Apoptosis assay using HepG2 cell line, PA1 and PC3 cell line and non cancerous cell line (NIH/3t3).	183
9.3.6	Evaluation of cell migration/scratch assay using HepG2 cell line, PA1 and PC3 cell line and non cancerous cell line (NIH/3T3).	190
9.3.7	Evaluation of colony formation/cell proliferation assay using HepG2 cell line, PA1 and PC3 cell line.	198
9.4	Conclusion	201

CHAPTER 10

203- 226

**TRANSCRIPTOME ANALYSIS OF CERVICAL
CANCER CELL HELA TREATED WITH GEDUNIN**

10.1	Introduction	203
------	--------------	-----

10.2	Experimental	205
10.2.1	Molecular Docking	205
10.2.2	Simulation	205
10.2.3	Cell line and culture assay	206
10.2.4	Total RNA extraction	206
10.2.5	Illumina 2x150 PE library preparation	207
	Quantity and quality check (QC) of library on Agilent 4200	
10.2.6	Tape Station	207
10.2.7	Cluster Generation and Sequencing	207
10.2.8	Data Analysis	208
10.2.9	Functional Enrichment Analysis	208
10.3	Result and Discussion	209
10.3.1	Molecular Docking	209
10.3.2	Simulation	210
	RNA Sequencing Transcriptome Analysis of gedunin	
10.3.3	Treatment	212
	Gene Ontology and KEGG Analysis of Differentially	
10.3.4	Expressed Genes	215
10.4	Conclusion	226

CHAPTER 11

Summary and Conclusions	227 - 231
References	232 - 269
List of Publications	270 - 271